Drug-induced lupus erythematosus syndrome. Immuno-pathological, electronmicroscopical and serological studies.
D000328:Adult; D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D001706:Biopsy; D003168:Complement Fixation Tests; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects*; D007106:Immune Sera; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007962:Leukocytes / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D011342:Procainamide / Q000009:adverse effects*; D011817:Rabbits / Q000276:immunology; D012867:Skin / Q000473:pathology
D000974:Antibodies, Antinuclear; D007106:Immune Sera; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D006830:Hydralazine; D011342:Procainamide